TGFB2 and non-small cell lung carcinoma: Moreover, a therapeutic vaccine known as Belagenpumatucel-L, which is comprised of four TGF-β2 interfering gene-modified, irradiated, allogeneic non-small cell lung cancer (NSCLC) cell lines, has also been evaluated in a phase III clinical trial (16).